nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—embryo—liver cancer	0.012	0.286	CbGeAlD
Lithium—Hyperthyroidism—Sorafenib—liver cancer	0.00901	0.056	CcSEcCtD
Lithium—IMPA1—liver—liver cancer	0.00751	0.18	CbGeAlD
Lithium—GRIA3—liver—liver cancer	0.00639	0.153	CbGeAlD
Lithium—Folliculitis—Sorafenib—liver cancer	0.00567	0.0352	CcSEcCtD
Lithium—IMPA2—liver—liver cancer	0.00564	0.135	CbGeAlD
Lithium—Hypothyroidism—Sorafenib—liver cancer	0.00555	0.0345	CcSEcCtD
Lithium—GSK3B—liver—liver cancer	0.00553	0.132	CbGeAlD
Lithium—GSK3A—liver—liver cancer	0.00481	0.115	CbGeAlD
Lithium—Dehydration—Sorafenib—liver cancer	0.0024	0.0149	CcSEcCtD
Lithium—Blindness—Epirubicin—liver cancer	0.00238	0.0148	CcSEcCtD
Lithium—Dry skin—Sorafenib—liver cancer	0.00237	0.0147	CcSEcCtD
Lithium—Gastritis—Sorafenib—liver cancer	0.00229	0.0142	CcSEcCtD
Lithium—Blindness—Doxorubicin—liver cancer	0.0022	0.0137	CcSEcCtD
Lithium—Optic neuritis—Epirubicin—liver cancer	0.00214	0.0133	CcSEcCtD
Lithium—Psoriasis—Epirubicin—liver cancer	0.00209	0.013	CcSEcCtD
Lithium—Folliculitis—Epirubicin—liver cancer	0.00209	0.013	CcSEcCtD
Lithium—Erectile dysfunction—Sorafenib—liver cancer	0.00206	0.0128	CcSEcCtD
Lithium—Weight decreased—Sorafenib—liver cancer	0.00202	0.0126	CcSEcCtD
Lithium—Optic neuritis—Doxorubicin—liver cancer	0.00198	0.0123	CcSEcCtD
Lithium—Folliculitis—Doxorubicin—liver cancer	0.00194	0.012	CcSEcCtD
Lithium—Psoriasis—Doxorubicin—liver cancer	0.00194	0.012	CcSEcCtD
Lithium—Hypercalcaemia—Epirubicin—liver cancer	0.00189	0.0118	CcSEcCtD
Lithium—Nystagmus—Epirubicin—liver cancer	0.00184	0.0115	CcSEcCtD
Lithium—Albuminuria—Epirubicin—liver cancer	0.00176	0.011	CcSEcCtD
Lithium—Hypercalcaemia—Doxorubicin—liver cancer	0.00175	0.0109	CcSEcCtD
Lithium—Scotoma—Epirubicin—liver cancer	0.00173	0.0108	CcSEcCtD
Lithium—Nystagmus—Doxorubicin—liver cancer	0.00171	0.0106	CcSEcCtD
Lithium—Skin ulcer—Epirubicin—liver cancer	0.00169	0.0105	CcSEcCtD
Lithium—Tinnitus—Sorafenib—liver cancer	0.00167	0.0104	CcSEcCtD
Lithium—Albuminuria—Doxorubicin—liver cancer	0.00163	0.0101	CcSEcCtD
Lithium—Glycosuria—Epirubicin—liver cancer	0.00163	0.0101	CcSEcCtD
Lithium—Scotoma—Doxorubicin—liver cancer	0.0016	0.00997	CcSEcCtD
Lithium—Arrhythmia—Sorafenib—liver cancer	0.0016	0.00993	CcSEcCtD
Lithium—Alopecia—Sorafenib—liver cancer	0.00158	0.00982	CcSEcCtD
Lithium—Skin ulcer—Doxorubicin—liver cancer	0.00156	0.00972	CcSEcCtD
Lithium—Dysgeusia—Sorafenib—liver cancer	0.00153	0.00948	CcSEcCtD
Lithium—Glycosuria—Doxorubicin—liver cancer	0.0015	0.00934	CcSEcCtD
Lithium—Oliguria—Epirubicin—liver cancer	0.00143	0.00888	CcSEcCtD
Lithium—Angioedema—Sorafenib—liver cancer	0.00142	0.00884	CcSEcCtD
Lithium—Syncope—Sorafenib—liver cancer	0.0014	0.00868	CcSEcCtD
Lithium—Dysarthria—Epirubicin—liver cancer	0.00139	0.00865	CcSEcCtD
Lithium—Loss of consciousness—Sorafenib—liver cancer	0.00137	0.00851	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—liver cancer	0.00134	0.00833	CcSEcCtD
Lithium—Arthralgia—Sorafenib—liver cancer	0.00133	0.00824	CcSEcCtD
Lithium—Oliguria—Doxorubicin—liver cancer	0.00132	0.00821	CcSEcCtD
Lithium—Dry mouth—Sorafenib—liver cancer	0.0013	0.00806	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—liver cancer	0.00129	0.008	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—liver cancer	0.00128	0.00795	CcSEcCtD
Lithium—Shock—Sorafenib—liver cancer	0.00125	0.00777	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—liver cancer	0.00124	0.00771	CcSEcCtD
Lithium—Anorexia—Sorafenib—liver cancer	0.00121	0.00753	CcSEcCtD
Lithium—Coma—Epirubicin—liver cancer	0.0012	0.00748	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—liver cancer	0.00118	0.00735	CcSEcCtD
Lithium—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00116	0.0072	CcSEcCtD
Lithium—Hypertonia—Epirubicin—liver cancer	0.00115	0.00717	CcSEcCtD
Lithium—Dyspepsia—Sorafenib—liver cancer	0.00112	0.00695	CcSEcCtD
Lithium—Coma—Doxorubicin—liver cancer	0.00111	0.00692	CcSEcCtD
Lithium—Decreased appetite—Sorafenib—liver cancer	0.0011	0.00687	CcSEcCtD
Lithium—Fatigue—Sorafenib—liver cancer	0.0011	0.00681	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—liver cancer	0.00107	0.00664	CcSEcCtD
Lithium—Gastrointestinal pain—Sorafenib—liver cancer	0.00104	0.00646	CcSEcCtD
Lithium—Abdominal pain—Sorafenib—liver cancer	0.001	0.00624	CcSEcCtD
Lithium—Body temperature increased—Sorafenib—liver cancer	0.001	0.00624	CcSEcCtD
Lithium—Lethargy—Epirubicin—liver cancer	0.000975	0.00606	CcSEcCtD
Lithium—Asthenia—Sorafenib—liver cancer	0.000912	0.00567	CcSEcCtD
Lithium—Lethargy—Doxorubicin—liver cancer	0.000902	0.00561	CcSEcCtD
Lithium—Ataxia—Epirubicin—liver cancer	0.000899	0.00558	CcSEcCtD
Lithium—Dehydration—Epirubicin—liver cancer	0.000889	0.00552	CcSEcCtD
Lithium—Dry skin—Epirubicin—liver cancer	0.000876	0.00544	CcSEcCtD
Lithium—Diarrhoea—Sorafenib—liver cancer	0.00087	0.0054	CcSEcCtD
Lithium—Gastritis—Epirubicin—liver cancer	0.000846	0.00526	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—liver cancer	0.000843	0.00524	CcSEcCtD
Lithium—Dizziness—Sorafenib—liver cancer	0.00084	0.00522	CcSEcCtD
Lithium—Ataxia—Doxorubicin—liver cancer	0.000831	0.00517	CcSEcCtD
Lithium—Dehydration—Doxorubicin—liver cancer	0.000822	0.00511	CcSEcCtD
Lithium—Dry skin—Doxorubicin—liver cancer	0.000811	0.00504	CcSEcCtD
Lithium—Vomiting—Sorafenib—liver cancer	0.000808	0.00502	CcSEcCtD
Lithium—Rash—Sorafenib—liver cancer	0.000801	0.00498	CcSEcCtD
Lithium—Dermatitis—Sorafenib—liver cancer	0.000801	0.00498	CcSEcCtD
Lithium—Headache—Sorafenib—liver cancer	0.000796	0.00495	CcSEcCtD
Lithium—Gastritis—Doxorubicin—liver cancer	0.000783	0.00486	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—liver cancer	0.00078	0.00485	CcSEcCtD
Lithium—Nausea—Sorafenib—liver cancer	0.000755	0.00469	CcSEcCtD
Lithium—Weight increased—Epirubicin—liver cancer	0.000752	0.00467	CcSEcCtD
Lithium—Weight decreased—Epirubicin—liver cancer	0.000747	0.00464	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—liver cancer	0.000745	0.00463	CcSEcCtD
Lithium—Drowsiness—Epirubicin—liver cancer	0.000736	0.00458	CcSEcCtD
Lithium—Weight increased—Doxorubicin—liver cancer	0.000696	0.00432	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—liver cancer	0.000691	0.0043	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—liver cancer	0.000689	0.00428	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—liver cancer	0.000681	0.00423	CcSEcCtD
Lithium—Bradycardia—Epirubicin—liver cancer	0.000673	0.00418	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—liver cancer	0.000623	0.00387	CcSEcCtD
Lithium—Tinnitus—Epirubicin—liver cancer	0.000616	0.00383	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—liver cancer	0.000591	0.00367	CcSEcCtD
Lithium—Alopecia—Epirubicin—liver cancer	0.000584	0.00363	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—liver cancer	0.00057	0.00354	CcSEcCtD
Lithium—Flatulence—Epirubicin—liver cancer	0.000567	0.00352	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—liver cancer	0.000564	0.0035	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—liver cancer	0.000546	0.0034	CcSEcCtD
Lithium—Vision blurred—Epirubicin—liver cancer	0.000542	0.00337	CcSEcCtD
Lithium—Alopecia—Doxorubicin—liver cancer	0.000541	0.00336	CcSEcCtD
Lithium—Agitation—Epirubicin—liver cancer	0.000529	0.00329	CcSEcCtD
Lithium—Flatulence—Doxorubicin—liver cancer	0.000525	0.00326	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—liver cancer	0.000521	0.00324	CcSEcCtD
Lithium—Vertigo—Epirubicin—liver cancer	0.000517	0.00321	CcSEcCtD
Lithium—Syncope—Epirubicin—liver cancer	0.000516	0.00321	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—liver cancer	0.000506	0.00314	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—liver cancer	0.000502	0.00312	CcSEcCtD
Lithium—Convulsion—Epirubicin—liver cancer	0.000499	0.0031	CcSEcCtD
Lithium—Arthralgia—Epirubicin—liver cancer	0.00049	0.00305	CcSEcCtD
Lithium—Agitation—Doxorubicin—liver cancer	0.000489	0.00304	CcSEcCtD
Lithium—Discomfort—Epirubicin—liver cancer	0.000484	0.00301	CcSEcCtD
Lithium—Dry mouth—Epirubicin—liver cancer	0.000479	0.00298	CcSEcCtD
Lithium—Vertigo—Doxorubicin—liver cancer	0.000478	0.00297	CcSEcCtD
Lithium—Syncope—Doxorubicin—liver cancer	0.000478	0.00297	CcSEcCtD
Lithium—Confusional state—Epirubicin—liver cancer	0.000474	0.00294	CcSEcCtD
Lithium—Oedema—Epirubicin—liver cancer	0.00047	0.00292	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—liver cancer	0.000468	0.00291	CcSEcCtD
Lithium—Shock—Epirubicin—liver cancer	0.000462	0.00287	CcSEcCtD
Lithium—Convulsion—Doxorubicin—liver cancer	0.000461	0.00287	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—liver cancer	0.000453	0.00282	CcSEcCtD
Lithium—Discomfort—Doxorubicin—liver cancer	0.000448	0.00278	CcSEcCtD
Lithium—Anorexia—Epirubicin—liver cancer	0.000448	0.00278	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—liver cancer	0.000443	0.00276	CcSEcCtD
Lithium—Hypotension—Epirubicin—liver cancer	0.000439	0.00273	CcSEcCtD
Lithium—Confusional state—Doxorubicin—liver cancer	0.000438	0.00272	CcSEcCtD
Lithium—Oedema—Doxorubicin—liver cancer	0.000435	0.0027	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000428	0.00266	CcSEcCtD
Lithium—Shock—Doxorubicin—liver cancer	0.000428	0.00266	CcSEcCtD
Lithium—Somnolence—Epirubicin—liver cancer	0.000418	0.0026	CcSEcCtD
Lithium—Anorexia—Doxorubicin—liver cancer	0.000414	0.00257	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—liver cancer	0.000413	0.00257	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—liver cancer	0.000408	0.00254	CcSEcCtD
Lithium—Hypotension—Doxorubicin—liver cancer	0.000406	0.00252	CcSEcCtD
Lithium—Fatigue—Epirubicin—liver cancer	0.000405	0.00252	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000396	0.00246	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—liver cancer	0.000387	0.00241	CcSEcCtD
Lithium—Somnolence—Doxorubicin—liver cancer	0.000386	0.0024	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—liver cancer	0.000384	0.00239	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—liver cancer	0.000383	0.00238	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—liver cancer	0.000378	0.00235	CcSEcCtD
Lithium—Fatigue—Doxorubicin—liver cancer	0.000375	0.00233	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—liver cancer	0.000371	0.00231	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—liver cancer	0.000371	0.00231	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—liver cancer	0.000358	0.00223	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—liver cancer	0.000355	0.00221	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—liver cancer	0.000344	0.00214	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—liver cancer	0.000344	0.00214	CcSEcCtD
Lithium—Asthenia—Epirubicin—liver cancer	0.000337	0.00209	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—liver cancer	0.000321	0.002	CcSEcCtD
Lithium—Asthenia—Doxorubicin—liver cancer	0.000312	0.00194	CcSEcCtD
Lithium—Dizziness—Epirubicin—liver cancer	0.000311	0.00193	CcSEcCtD
Lithium—Vomiting—Epirubicin—liver cancer	0.000299	0.00186	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—liver cancer	0.000297	0.00185	CcSEcCtD
Lithium—Rash—Epirubicin—liver cancer	0.000296	0.00184	CcSEcCtD
Lithium—Dermatitis—Epirubicin—liver cancer	0.000296	0.00184	CcSEcCtD
Lithium—Headache—Epirubicin—liver cancer	0.000294	0.00183	CcSEcCtD
Lithium—Dizziness—Doxorubicin—liver cancer	0.000287	0.00179	CcSEcCtD
Lithium—Nausea—Epirubicin—liver cancer	0.000279	0.00173	CcSEcCtD
Lithium—Vomiting—Doxorubicin—liver cancer	0.000276	0.00172	CcSEcCtD
Lithium—Rash—Doxorubicin—liver cancer	0.000274	0.0017	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—liver cancer	0.000274	0.0017	CcSEcCtD
Lithium—Headache—Doxorubicin—liver cancer	0.000272	0.00169	CcSEcCtD
Lithium—Nausea—Doxorubicin—liver cancer	0.000258	0.0016	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—liver cancer	0.000145	0.000182	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCR4—liver cancer	0.000145	0.000182	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—liver cancer	0.000145	0.000182	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—liver cancer	0.000145	0.000182	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—liver cancer	0.000145	0.000182	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—IL6—liver cancer	0.000145	0.000181	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—liver cancer	0.000143	0.00018	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1B—liver cancer	0.000143	0.00018	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—liver cancer	0.000142	0.000178	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—liver cancer	0.000142	0.000178	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—liver cancer	0.000142	0.000178	CbGpPWpGaD
Lithium—GSK3A—Disease—H2AFX—liver cancer	0.000141	0.000177	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—liver cancer	0.00014	0.000175	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—liver cancer	0.000139	0.000174	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1B—liver cancer	0.000138	0.000173	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—liver cancer	0.000137	0.000172	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—JUN—liver cancer	0.000137	0.000171	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—liver cancer	0.000136	0.00017	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—liver cancer	0.000134	0.000168	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—liver cancer	0.000133	0.000167	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1A—liver cancer	0.000132	0.000166	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2L1—liver cancer	0.000132	0.000166	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—liver cancer	0.000131	0.000165	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RAF1—liver cancer	0.000131	0.000164	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—liver cancer	0.000131	0.000164	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—liver cancer	0.00013	0.000163	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CD—liver cancer	0.00013	0.000163	CbGpPWpGaD
Lithium—GSK3B—Disease—GOT1—liver cancer	0.000129	0.000162	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRKCE—liver cancer	0.000129	0.000162	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK8—liver cancer	0.000129	0.000162	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—liver cancer	0.000128	0.000161	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—liver cancer	0.000128	0.00016	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—liver cancer	0.000127	0.00016	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1A—liver cancer	0.000127	0.000159	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK14—liver cancer	0.000125	0.000157	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—liver cancer	0.000125	0.000157	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—liver cancer	0.000125	0.000156	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CD—liver cancer	0.000124	0.000156	CbGpPWpGaD
Lithium—GSK3B—Immune System—ABL1—liver cancer	0.000123	0.000154	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—liver cancer	0.000123	0.000154	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—liver cancer	0.000121	0.000151	CbGpPWpGaD
Lithium—GSK3B—Disease—PRKCE—liver cancer	0.000119	0.00015	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—liver cancer	0.000119	0.000149	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—liver cancer	0.000119	0.000149	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—liver cancer	0.000118	0.000149	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RAF1—liver cancer	0.000116	0.000145	CbGpPWpGaD
Lithium—GSK3B—Immune System—HGF—liver cancer	0.000116	0.000145	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADAM17—liver cancer	0.000115	0.000144	CbGpPWpGaD
Lithium—GSK3B—Immune System—CSF2—liver cancer	0.000114	0.000143	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—liver cancer	0.000114	0.000143	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—liver cancer	0.000114	0.000143	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—liver cancer	0.000113	0.000142	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRKCE—liver cancer	0.000113	0.000142	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CB—liver cancer	0.000113	0.000142	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MTOR—liver cancer	0.000113	0.000142	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—liver cancer	0.000112	0.00014	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—liver cancer	0.000111	0.00014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—liver cancer	0.000111	0.000139	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RAF1—liver cancer	0.000111	0.000139	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—liver cancer	0.00011	0.000138	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MTOR—liver cancer	0.000108	0.000136	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CB—liver cancer	0.000108	0.000136	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSMA4—liver cancer	0.000108	0.000135	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSMD10—liver cancer	0.000108	0.000135	CbGpPWpGaD
Lithium—GSK3A—Disease—APC—liver cancer	0.000107	0.000135	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—liver cancer	0.000107	0.000134	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—liver cancer	0.000107	0.000134	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—liver cancer	0.000107	0.000134	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1B—liver cancer	0.000106	0.000133	CbGpPWpGaD
Lithium—GSK3B—Disease—H2AFX—liver cancer	0.000104	0.000131	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—liver cancer	0.000102	0.000128	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CD—liver cancer	0.000102	0.000128	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1B—liver cancer	0.000102	0.000128	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—liver cancer	0.000101	0.000127	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—liver cancer	0.000101	0.000127	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—liver cancer	0.000101	0.000127	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—liver cancer	0.000101	0.000126	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—liver cancer	0.0001	0.000126	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CSF2—liver cancer	0.0001	0.000125	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—liver cancer	9.98e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—liver cancer	9.89e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—liver cancer	9.86e-05	0.000124	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—H2AFX—liver cancer	9.86e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—liver cancer	9.78e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—liver cancer	9.78e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—liver cancer	9.74e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—liver cancer	9.68e-05	0.000121	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK8—liver cancer	9.55e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—liver cancer	9.44e-05	0.000118	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CD—liver cancer	9.43e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—liver cancer	9.41e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—liver cancer	9.4e-05	0.000118	CbGpPWpGaD
Lithium—GSK3A—Disease—SERPINE1—liver cancer	9.33e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—liver cancer	9.32e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK14—liver cancer	9.26e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—liver cancer	9.16e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Immune System—RAF1—liver cancer	9.12e-05	0.000114	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—liver cancer	9.11e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—liver cancer	9.08e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—liver cancer	8.95e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—liver cancer	8.92e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—liver cancer	8.9e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—liver cancer	8.9e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—liver cancer	8.62e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—liver cancer	8.56e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—liver cancer	8.49e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Disease—RAF1—liver cancer	8.42e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKCE—liver cancer	8.36e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—liver cancer	8.36e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—liver cancer	8.28e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—liver cancer	8.25e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—liver cancer	8.22e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—liver cancer	8.22e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—liver cancer	8.18e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—liver cancer	8.16e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK14—liver cancer	8.1e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—liver cancer	7.95e-05	9.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—liver cancer	7.95e-05	9.97e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—liver cancer	7.93e-05	9.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—liver cancer	7.92e-05	9.93e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—liver cancer	7.9e-05	9.91e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—liver cancer	7.89e-05	9.9e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—F2—liver cancer	7.85e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—liver cancer	7.72e-05	9.68e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—liver cancer	7.71e-05	9.67e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—liver cancer	7.61e-05	9.55e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—liver cancer	7.55e-05	9.47e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK8—liver cancer	7.53e-05	9.44e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—liver cancer	7.51e-05	9.42e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—liver cancer	7.51e-05	9.42e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—liver cancer	7.5e-05	9.4e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—liver cancer	7.45e-05	9.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CSF2—liver cancer	7.39e-05	9.27e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—liver cancer	7.31e-05	9.17e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—liver cancer	7.29e-05	9.14e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—H2AFX—liver cancer	7.29e-05	9.14e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—liver cancer	7.21e-05	9.05e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—liver cancer	7.2e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—liver cancer	7.12e-05	8.93e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—liver cancer	7.06e-05	8.86e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—liver cancer	6.97e-05	8.74e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—liver cancer	6.9e-05	8.66e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SERPINE1—liver cancer	6.89e-05	8.65e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—liver cancer	6.89e-05	8.64e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—liver cancer	6.88e-05	8.63e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAF1—liver cancer	6.74e-05	8.45e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—liver cancer	6.61e-05	8.29e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—liver cancer	6.6e-05	8.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—liver cancer	6.59e-05	8.26e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—liver cancer	6.58e-05	8.25e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—liver cancer	6.58e-05	8.25e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SERPINE1—liver cancer	6.53e-05	8.19e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—liver cancer	6.37e-05	7.99e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—liver cancer	6.37e-05	7.99e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—liver cancer	6.35e-05	7.97e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—RAF1—liver cancer	6.22e-05	7.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—liver cancer	6.17e-05	7.74e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—liver cancer	6.12e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—liver cancer	6.1e-05	7.65e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—liver cancer	6.07e-05	7.62e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—liver cancer	6.07e-05	7.62e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—liver cancer	6.04e-05	7.58e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—liver cancer	6.03e-05	7.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK14—liver cancer	5.99e-05	7.51e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—liver cancer	5.91e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—liver cancer	5.9e-05	7.4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAF1—liver cancer	5.9e-05	7.4e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—liver cancer	5.89e-05	7.39e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—liver cancer	5.88e-05	7.37e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—liver cancer	5.87e-05	7.37e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—liver cancer	5.83e-05	7.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—F2—liver cancer	5.8e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—liver cancer	5.76e-05	7.22e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—liver cancer	5.76e-05	7.22e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—liver cancer	5.7e-05	7.15e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—liver cancer	5.7e-05	7.15e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—liver cancer	5.63e-05	7.06e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK8—liver cancer	5.56e-05	6.98e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—liver cancer	5.55e-05	6.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—liver cancer	5.55e-05	6.96e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—liver cancer	5.45e-05	6.84e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—liver cancer	5.43e-05	6.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—liver cancer	5.4e-05	6.78e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—liver cancer	5.4e-05	6.78e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—liver cancer	5.39e-05	6.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—liver cancer	5.3e-05	6.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—liver cancer	5.29e-05	6.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—liver cancer	5.26e-05	6.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—liver cancer	5.22e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—liver cancer	5.15e-05	6.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—liver cancer	5.14e-05	6.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—liver cancer	5.1e-05	6.4e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—liver cancer	5.08e-05	6.38e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—liver cancer	5.02e-05	6.3e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—liver cancer	5.01e-05	6.29e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—liver cancer	5e-05	6.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—liver cancer	4.99e-05	6.25e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—liver cancer	4.88e-05	6.12e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK8—liver cancer	4.87e-05	6.1e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SERPINE1—liver cancer	4.83e-05	6.05e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—liver cancer	4.81e-05	6.03e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—liver cancer	4.69e-05	5.89e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—liver cancer	4.64e-05	5.82e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—liver cancer	4.49e-05	5.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—liver cancer	4.45e-05	5.58e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—liver cancer	4.44e-05	5.57e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—liver cancer	4.43e-05	5.56e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—liver cancer	4.37e-05	5.48e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—liver cancer	4.36e-05	5.47e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RAF1—liver cancer	4.36e-05	5.47e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—liver cancer	4.35e-05	5.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—liver cancer	4.25e-05	5.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—liver cancer	4.25e-05	5.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—liver cancer	4.13e-05	5.19e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—liver cancer	4.12e-05	5.17e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—liver cancer	4.09e-05	5.14e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—liver cancer	4.03e-05	5.06e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—liver cancer	4.01e-05	5.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—liver cancer	3.99e-05	5.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—liver cancer	3.91e-05	4.91e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—liver cancer	3.91e-05	4.9e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—liver cancer	3.82e-05	4.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—liver cancer	3.81e-05	4.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—liver cancer	3.8e-05	4.77e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—liver cancer	3.77e-05	4.73e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—liver cancer	3.71e-05	4.65e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—liver cancer	3.7e-05	4.64e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—liver cancer	3.7e-05	4.64e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—liver cancer	3.68e-05	4.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK8—liver cancer	3.6e-05	4.51e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—liver cancer	3.55e-05	4.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—liver cancer	3.51e-05	4.4e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—liver cancer	3.43e-05	4.3e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—liver cancer	3.4e-05	4.26e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—liver cancer	3.32e-05	4.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—liver cancer	3.29e-05	4.12e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—liver cancer	3.28e-05	4.11e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—liver cancer	3.28e-05	4.11e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—liver cancer	3.25e-05	4.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—liver cancer	3.11e-05	3.9e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—liver cancer	3.05e-05	3.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—liver cancer	3.05e-05	3.82e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—liver cancer	3.03e-05	3.79e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—liver cancer	2.87e-05	3.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—liver cancer	2.82e-05	3.54e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—liver cancer	2.59e-05	3.25e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—liver cancer	2.51e-05	3.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—liver cancer	2.4e-05	3.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—liver cancer	2.3e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—liver cancer	2.12e-05	2.66e-05	CbGpPWpGaD
